Mereo BioPharma Group PLC (MREO)
3.20
-0.07
(-2.14%)
USD |
NASDAQ |
May 17, 16:00
3.20
0.00 (0.00%)
After-Hours: 20:00
Mereo BioPharma Group SG&A Expense (Quarterly): 5.906M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 5.906M |
| June 30, 2023 | 5.593M |
| Date | Value |
|---|---|
| March 31, 2023 | 6.45M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
5.593M
Minimum
Jun 2023
6.45M
Maximum
Mar 2023
5.983M
Average
5.906M
Median
Mar 2024
SG&A Expense (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana PLC | 1.597M |
| TC BioPharm (Holdings) PLC | -- |
| Adaptimmune Therapeutics PLC | 19.73M |
| Autolus Therapeutics PLC | 15.73M |